NEW YORK – Molecular Diagnostics startup Scanogen is developing a direct-from-blood sepsis test that could help to identify the causes of bloodstream infections within two hours rather than days by ...

NEW YORK – The European Commission is in the process of drafting new biotechnology-focused legislation that will impact manufacturers of in vitro diagnostics and medical devices. The envisioned ...

The test is a bead-based multiplexed immunoassay that also utilizes a machine-learning classifier to determine whether a ...

The company recently published a study showing that elemental patterns in single strands of hair are different in patients ...

The company's SwiftX Virus extraction kit is used to prepare viral RNA and bacterial DNA for PCR-based testing for six arboviruses and one bacterial target.

The fully automated PCR-based testing system will be used in microbiology and virology labs to aid the detection of viral and bacterial causes of infectious diseases.

The company plans to launch in 2026 a program that will provide labs with scanners free of charge in exchange for volume-based payments for biomarker tests.

A new test to help select colorectal cancer therapy is the first in a menu of rapid cartridge-based tests the firm is planning to support cancer testing.

The test uses autofluorescent single-walled carbon nanotubes to detect bacterial cell death in antimicrobial-containing microfluidic channels.

The grant will support the development of RapiDetect CT/NG, the company's molecular test for Chlamydia trachomatis and Neisseria gonorrhoeae.

The agency said that during emergencies it will balance the risks of delaying access to tests compared with the risks of harm from inaccurate test results.